William M. Facteau , BA

Chairman

EarLens
Menlo Park, CA

William M. Facteau joined EarLens Corporation as Chairman, President & CEO in November of 2013. Previously he acted as the Vice Chairman of ExploraMed Development, LLC, a medical device incubator based on the West Coast and as an Entrepreneur in Residence at New Enterprise Associates (NEA). He also serves on the Board of Directors of ExploraMed Development LLC, NeoTract, Inc., and Autonomic Technologies, Inc. (ATI). Facteau was formerly the Chairman of the Board for Cabochon Aesthetics which was acquired in 2014 by Ulthera as well as an independent board member at CV Ingenuity (CVI), Inc., which was acquired by Covidien in 2013.

Previous to this, Mr. Facteau was at Johnson and Johnson (JNJ) from January 2010 through January 2012 as Worldwide President of their ENT Division. Facteau joined JNJ via the $800M acquisition of Acclarent, Inc. where he served as the President, CEO, and a member of the Board of Directors since the company's formation in 2004. Under Facteau's leadership, the company went from concept to acquisition in 5 1/2years, raised over $100M, created jobs for approximately 400 employees, grew revenues to $100M and became profitable.

Prior to joining Acclarent, Mr. Facteau was the General Manager of the Endovascular Division at Abbott Vascular, where he served as a member of the executive team and created the entry strategy for Abbott to participate in the peripheral vascular space. Mr. Facteau joined Abbott Laboratories via the $683 million acquisition of Perclose, a vessel closure company, where he was Sales Director. From July 1993 to April 1998, Mr. Facteau worked in a number of sales and sales management positions at United States Surgical Corporation. Mr. Facteau received his B.A. in Political Science from the University of Connecticut, and is a named inventor on several issued patents.